208 related articles for article (PubMed ID: 2971659)
41. Characterization of Binding Properties of Individual Functional Sites of Human Complement Factor H.
Haque A; Cortes C; Alam MN; Sreedhar M; Ferreira VP; Pangburn MK
Front Immunol; 2020; 11():1728. PubMed ID: 32849614
[TBL] [Abstract][Full Text] [Related]
42. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules.
Medicus RG; Melamed J; Arnaout MA
Eur J Immunol; 1983 Jun; 13(6):465-70. PubMed ID: 6222909
[TBL] [Abstract][Full Text] [Related]
43. Characterization of the human glomerular C3 receptor as the C3b/C4b complement type one (CR1) receptor.
Fischer E; Appay MD; Cook J; Kazatchkine MD
J Immunol; 1986 Feb; 136(4):1373-7. PubMed ID: 2418113
[TBL] [Abstract][Full Text] [Related]
44. Human complement component C4. Structural studies on the fragments derived from C4b by cleavage with C3b inactivator.
Press EM; Gagnon J
Biochem J; 1981 Nov; 199(2):351-7. PubMed ID: 6978710
[TBL] [Abstract][Full Text] [Related]
45. Phosphorylation of C3 by a casein kinase released from activated human platelets increases opsonization of immune complexes and binding to complement receptor type 1.
Nilsson-Ekdahl K; Nilsson B
Eur J Immunol; 2001 Apr; 31(4):1047-54. PubMed ID: 11298329
[TBL] [Abstract][Full Text] [Related]
46. A study of the breakdown of the third component of human complement (C3).
Fontaine M; Rivat C
Ann Immunol (Paris); 1979; 130C(3):349-66. PubMed ID: 475341
[TBL] [Abstract][Full Text] [Related]
47. Interaction of iC3b with recombinant isotypic and chimeric forms of CR2.
Kalli KR; Ahearn JM; Fearon DT
J Immunol; 1991 Jul; 147(2):590-4. PubMed ID: 1830068
[TBL] [Abstract][Full Text] [Related]
48. Disease-associated loss of erythrocyte complement receptors (CR1, C3b receptors) in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation.
Ross GD; Yount WJ; Walport MJ; Winfield JB; Parker CJ; Fuller CR; Taylor RP; Myones BL; Lachmann PJ
J Immunol; 1985 Sep; 135(3):2005-14. PubMed ID: 4020137
[TBL] [Abstract][Full Text] [Related]
49. C3 receptors on human lymphocyte subsets and recruitment of ADCC effector cells by C3 fragments.
Wåhlin B; Perlmann H; Perlmann P; Schreiber RD; Müller-Eberhard HJ
J Immunol; 1983 Jun; 130(6):2831-6. PubMed ID: 6222118
[TBL] [Abstract][Full Text] [Related]
50. Glomerular CR1 express in situ cofactor activity for degradation of C3b.
Vedeler CA; Matre R; Iversen BM
Int Arch Allergy Appl Immunol; 1990; 92(1):60-3. PubMed ID: 2147176
[TBL] [Abstract][Full Text] [Related]
51. C3b2-IgG complexes retain dimeric C3 fragments at all levels of inactivation.
Jelezarova E; Luginbuehl A; Lutz HU
J Biol Chem; 2003 Dec; 278(51):51806-12. PubMed ID: 14527961
[TBL] [Abstract][Full Text] [Related]
52. A novel cleavage product of human complement component C3 with structural and functional properties of cobra venom factor.
O'Keefe MC; Caporale LH; Vogel CW
J Biol Chem; 1988 Sep; 263(25):12690-7. PubMed ID: 3045125
[TBL] [Abstract][Full Text] [Related]
53. Breakdown of C3 after complement activation. Identification of a new fragment C3g, using monoclonal antibodies.
Lachmann PJ; Pangburn MK; Oldroyd RG
J Exp Med; 1982 Jul; 156(1):205-16. PubMed ID: 6177820
[TBL] [Abstract][Full Text] [Related]
54. Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins.
Klickstein LB; Wong WW; Smith JA; Weis JH; Wilson JG; Fearon DT
J Exp Med; 1987 Apr; 165(4):1095-112. PubMed ID: 2951479
[TBL] [Abstract][Full Text] [Related]
55. Action of the C3b-inactivator on the cell-bound C3b.
Law SK; Fearon DT; Levine RP
J Immunol; 1979 Mar; 122(3):759-65. PubMed ID: 448074
[TBL] [Abstract][Full Text] [Related]
56. Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement.
Weis JJ; Fearon DT; Klickstein LB; Wong WW; Richards SA; de Bruyn Kops A; Smith JA; Weis JH
Proc Natl Acad Sci U S A; 1986 Aug; 83(15):5639-43. PubMed ID: 3016712
[TBL] [Abstract][Full Text] [Related]
57. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library.
Sahu A; Kay BK; Lambris JD
J Immunol; 1996 Jul; 157(2):884-91. PubMed ID: 8752942
[TBL] [Abstract][Full Text] [Related]
58. Characterization of a monoclonal antibody MoAb bH6 reacting with a neoepitope of human C3 expressed on C3b, iC3b, and C3c.
Garred P; Mollnes TE; Lea T; Fischer E
Scand J Immunol; 1988 Mar; 27(3):319-27. PubMed ID: 2451273
[TBL] [Abstract][Full Text] [Related]
59. Interaction of C3 with antigen-antibody complexes in the process of solubilization of immune precipitates.
Takata Y; Tamura N; Fujita T
J Immunol; 1984 May; 132(5):2531-7. PubMed ID: 6232320
[TBL] [Abstract][Full Text] [Related]
60. Complement receptor is an inhibitor of the complement cascade.
Iida K; Nussenzweig V
J Exp Med; 1981 May; 153(5):1138-50. PubMed ID: 6910481
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
